search
Back to results

Correlation Research Study: IQ2, NcIQ and IQ101 (NMT-CT)

Primary Purpose

Heart Failure, Dyspnea, Hypertension

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Noninvasive Hemodynamic Patient Monitor
Sponsored by
Noninvasive Medical Technologies, Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Heart Failure focused on measuring Noninvasive, Hemodynamic, Monitoring, Critical Care, Swan-Ganz

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria:

  • Age - 18-80 years
  • Weight - 80-300 pounds
  • Height - 5.0 feet - 6feet 4 inches Exclusion Criteria
  • Ongoing medical emergency or acute medical illness
  • NcIQ or ECG electrode adhesive allergy or sensitivity

Sites / Locations

    Outcomes

    Primary Outcome Measures

    A direct correlation between output parameters of IQ2/NcIQ to IQ101

    Secondary Outcome Measures

    Full Information

    First Posted
    June 22, 2007
    Last Updated
    June 22, 2007
    Sponsor
    Noninvasive Medical Technologies, Inc.
    Collaborators
    University of Florida, Shand's Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00491777
    Brief Title
    Correlation Research Study: IQ2, NcIQ and IQ101
    Acronym
    NMT-CT
    Official Title
    Correlation Study of NMT's IQ2, NcIQ and Its' Predicate Technology, IQ101.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2007
    Overall Recruitment Status
    Completed
    Study Start Date
    June 2007 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    June 2007 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Noninvasive Medical Technologies, Inc.
    Collaborators
    University of Florida, Shand's Medical Center

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The new NcIQ thoracic impedance monitor is based on the predicate device, the IQ101. The new model uses the same 3-dimensional signal averaging as the original device, but also include second radio frequency signal to permit the device to work "wirelessly", i.e., without electrode lead attachments to the patient. This study seeks to 1) validate the use of the new device and confirm the correlation of the IQ101 and NcIQ. 2) Evaluate the ease of the new device. The new IQ2 thoracic impedance monitor is based on the predicate device, the IQ101. The new model uses the same 3-dimensional signal averaging as the original device, but with smaller housing and updated operating software. This study seeks to 1) Validate the use of the new device and confirm the correlation of the IQ101 and IQ2. 2) Compare the ease of the devices.
    Detailed Description
    The IQ101 is the first generation of the non invasive cardiograph. This device uses impedance to a micro-electric field passing from the electrodes. The NcIQ uses Radio frequencies and the same 3 dimensional signal averaging algorithm used in the IQ101 to generate hemodynamic data. The radio waves enables the device to work without the contact lead arrays used in the IQ2 and can take measurements without even contacting the patient, hence can be applied through clothing and is simple to apply. This makes the potential use by first responders a possibility. The device measures the change in the radio wave reflection during the cardiac cycle to estimate ardiac function. Specifically, it measures cardiac output, the amount of blood pumped per minute, and other hemodynamic parameters previously only measurable with invasive catheters. The data us used to generate a LIFESCORE and can measure and report dangerous trends to the caretaker. The device has a companion device to download the data for the hospital providers to create a seamless transfer of care. The new device uses technology similar to the previous generation machine but has been miniaturized, given updated operating system, and newer computer technology that helped make the device smaller, and faster. The underlying patented algorithm was not changed. Therefore, it is expected to provide the same degree of accuracy and precision as the predicate device. The IQ101 is the first generation of the non invasive cardiograph. This device uses impedance to a micro-electric field passing from the electrodes. The device can use the impedance and the change in the impedance during the cardiac cycle to estimate thoracic fluid volumes and cardiac function. Specifically, it measures cardiac output, the amount of blood pumped per minute, and other hemodynamic parameters previously only measurable with invasive catheters. There are many studies documenting the device's performance. The new device uses the same technology but has been modernized with updated operating system, and newer computer technology that helped make the device smaller, and faster. The device has also been redesigned to make operator use simpler and reduce the number wires involved. The underlying patented algorithm was not changed. Therefore, it is expected to provide the same degree of accuracy and precision as the predicate device with simplified user interface and lighter, smaller, more portable housing to improve ease of use.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Heart Failure, Dyspnea, Hypertension, Pacemaker, Trauma
    Keywords
    Noninvasive, Hemodynamic, Monitoring, Critical Care, Swan-Ganz

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Phase 1
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    25 (Actual)

    8. Arms, Groups, and Interventions

    Intervention Type
    Device
    Intervention Name(s)
    Noninvasive Hemodynamic Patient Monitor
    Primary Outcome Measure Information:
    Title
    A direct correlation between output parameters of IQ2/NcIQ to IQ101

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion criteria: Age - 18-80 years Weight - 80-300 pounds Height - 5.0 feet - 6feet 4 inches Exclusion Criteria Ongoing medical emergency or acute medical illness NcIQ or ECG electrode adhesive allergy or sensitivity
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Kevin Ferguson, MD
    Organizational Affiliation
    Shand's Hospital
    Official's Role
    Study Chair
    First Name & Middle Initial & Last Name & Degree
    Joseph A Tyndall, MD
    Organizational Affiliation
    Shand's Hospital
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    David Seaberg, MD
    Organizational Affiliation
    Shand's Hospital
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Correlation Research Study: IQ2, NcIQ and IQ101

    We'll reach out to this number within 24 hrs